Phase-Changing Matrix for 3D Organoid Culture with Mesenchymal Stem Cells

The USPTO published Application US20260092254A1 claiming a composition for three-dimensional cell and organoid culture comprising a phase-changing matrix with partially ordered polypeptide encapsulating bone-marrow derived or adipose-derived mesenchymal stem cells. The application was filed on September 21, 2023 (Application No. 19113814). This publication provides public notice of the claimed invention for examination purposes.

Cell Based Assays for Botulinum Neurotoxins Serotype-Specific

USPTO published patent application US20260092255A1 for serotype-specific cell-based assays used in characterizing Clostridia botulinum neurotoxins. The assays utilize genetically modified cells capable of discriminating between different serotypes of clostridium neurotoxins without requiring serotype-specific neutralizing antibodies or competing heavy chains. Inventors: Ward Tucker, Francis Mark Dunning, Tim Piazza. Application No. 18920316.

Pepmixes for Multiviral CTL Generation

USPTO published patent application US20260092256A1 by Baylor College of Medicine covering methods of generating CTLs (cytotoxic T lymphocytes) targeting antigens from multiple viruses. The invention uses peptide mixtures exposed to PBMCs with IL4 and IL7 expansion. Published April 2, 2026, Application No. 19020866.

Methods for Generating Hematopoietic Progenitor Cells

The USPTO published patent application US20260092257A1 covering methods for generating human CD34+, CD43+, and CD90+ hematopoietic progenitor cells from hematopoietic stem cells using chemically-defined culture media. The application was filed October 2, 2025, under Application No. 19347888. Inventors include Angelica Gomes Ueltschy and Michael Elias.

Monitoring Assay Performance

The European Patent Office published patent application EP4639562A1 for Genentech, Inc., titled 'Monitoring Assay Performance.' The invention relates to methods and systems for monitoring assay performance and quality control in healthcare diagnostics. The patent was published March 25, 2026, with designated states covering all EPC contracting states.

Vaccine Management System for Preventing Vaccination Accidents

The European Patent Office published patent application EP4641582A1 for Real Time Medi Check Corp's vaccine management system designed to prevent vaccination accidents caused by incorrect vaccination and misregistration. The system covers technology for managing vaccination services and includes claims related to health informatics, tracking, and safety mechanisms.

Decision-making Assistant Tool for Health Informatics

The European Patent Office published patent application EP4634925A1 by Laboratory Corporation of America Holdings (Labcorp) for a decision-making assistant tool in health informatics. The invention is classified under G16H 10/40 and G16H 15/00, with inventors BERBERIAN, Lance, DE VRIES, Enno, LUNK, Jessie, and MOGOLOWITZ, Glenn. The application designates multiple European states including DE, FR, GB, IT, NL, and others.

Closed-Loop Neuromodulation Sleep Patent

The European Patent Office published patent application EP4633707A1 for Elemind Technologies, Inc., covering a closed-loop neuromodulation system for modulating sleep-related oscillations. The invention relates to methods and systems for detecting and responding to sleep states using real-time neural monitoring and adaptive stimulation. International patent classifications include A61M 21/00, A61B 5/00, and G16H 20/00.

Method for Providing Insight Notification on a Display Device Concerning Analyte Data

The European Patent Office published patent EP4634929A1, filed by DexCom, Inc., covering a method for providing insight notifications on a display device concerning analyte data, specifically glucose monitoring. The patent names 8 inventors and covers designated European states including all EU member states plus Switzerland, Norway, and other EEA countries.

Interleukin-2 for Treating Autism Spectrum Disorder

USPTO published patent application US20260092095A1 by INSERM covering interleukin-2 (IL-2) for treating autism spectrum disorder (ASD). The application also extends to preventing ASD in at-risk children or through maternal administration during pregnancy. Assignee is INSERM (Institut National de la Santé et de la Recherche Médicale, France).